CN107624071A - 肺癌治疗方法 - Google Patents

肺癌治疗方法 Download PDF

Info

Publication number
CN107624071A
CN107624071A CN201680028727.8A CN201680028727A CN107624071A CN 107624071 A CN107624071 A CN 107624071A CN 201680028727 A CN201680028727 A CN 201680028727A CN 107624071 A CN107624071 A CN 107624071A
Authority
CN
China
Prior art keywords
fra
antibody
seq
ser
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680028727.8A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼尔·约翰·奥沙尼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Corp of North America
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of CN107624071A publication Critical patent/CN107624071A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201680028727.8A 2015-04-17 2016-04-14 肺癌治疗方法 Pending CN107624071A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149184P 2015-04-17 2015-04-17
US62/149,184 2015-04-17
PCT/US2016/027497 WO2016168440A1 (en) 2015-04-17 2016-04-14 Methods for treating lung cancer

Publications (1)

Publication Number Publication Date
CN107624071A true CN107624071A (zh) 2018-01-23

Family

ID=55809240

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680028727.8A Pending CN107624071A (zh) 2015-04-17 2016-04-14 肺癌治疗方法

Country Status (13)

Country Link
US (1) US20180125970A1 (https=)
EP (1) EP3283886B1 (https=)
JP (1) JP2018516244A (https=)
KR (1) KR20170137848A (https=)
CN (1) CN107624071A (https=)
AU (1) AU2016248222A1 (https=)
BR (1) BR112017022320A2 (https=)
CA (1) CA2983126A1 (https=)
IL (1) IL255079A0 (https=)
MX (1) MX2017013390A (https=)
RU (1) RU2718780C9 (https=)
SG (1) SG11201708546UA (https=)
WO (1) WO2016168440A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110221052A (zh) * 2019-06-17 2019-09-10 昆山德诺瑞尔生物科技有限公司 Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
EP3153178A4 (en) * 2014-06-06 2017-12-20 Kyowa Hakko Kirin Co., Ltd. Method for treating cancer patients using folr1 targeted drug and antifolate, and drug
US10822410B2 (en) 2016-11-23 2020-11-03 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
CN115925952A (zh) 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
MA52300A (fr) * 2018-06-18 2021-04-21 Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer
IL314452A (en) * 2022-03-11 2024-09-01 Astrazeneca Ab Scoring method for anti-frα antibody-drug treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090274697A1 (en) * 2004-02-12 2009-11-05 Luigi Grasso Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
US8124083B2 (en) * 2005-04-22 2012-02-28 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
AU2011323124C1 (en) 2010-11-05 2016-09-22 Eisai Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
PL2731972T3 (pl) * 2011-07-15 2018-06-29 Eisai R&D Management Co., Ltd. Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090274697A1 (en) * 2004-02-12 2009-11-05 Luigi Grasso Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
US8124083B2 (en) * 2005-04-22 2012-02-28 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THOMAS, ANISH; MALTZMAN, JULIA; HASSAN, RAFFIT: "Farletuzumab in lung cancer", 《LUNG CANCER》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110221052A (zh) * 2019-06-17 2019-09-10 昆山德诺瑞尔生物科技有限公司 Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用

Also Published As

Publication number Publication date
IL255079A0 (en) 2017-12-31
US20180125970A1 (en) 2018-05-10
WO2016168440A1 (en) 2016-10-20
EP3283886B1 (en) 2020-01-15
MX2017013390A (es) 2018-06-13
RU2718780C9 (ru) 2020-07-08
AU2016248222A1 (en) 2017-11-09
BR112017022320A2 (en) 2018-07-24
RU2718780C2 (ru) 2020-04-14
SG11201708546UA (en) 2017-11-29
RU2017136863A (ru) 2019-05-17
JP2018516244A (ja) 2018-06-21
EP3283886A1 (en) 2018-02-21
RU2017136863A3 (https=) 2019-08-21
CA2983126A1 (en) 2016-10-20
KR20170137848A (ko) 2017-12-13

Similar Documents

Publication Publication Date Title
EP3283886B1 (en) Methods for treating lung cancer
CA2764386C (en) P95-her2 antibodies and uses thereof
US20190202930A1 (en) Methods for treatment of ovarian cancer
JP2019524706A (ja) Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
US10221240B2 (en) Methods for treatment of gastric cancer
US12275780B2 (en) Monoclonal antibodies against Ambra-1
JP2015108639A (ja) タキサン型化学療法剤用のインジケータとしてのｓｅｒ４７３でのａｋｔリン酸化反応
US20190154694A1 (en) Detection and treatment of cancer
WO2022154037A1 (ja) がんの予後バイオマーカー
US12455289B2 (en) Monoclonal antibodies against loricrin
EP2559440A2 (en) A microvesicle membrane protein and application thereof
JP5145549B2 (ja) 腫瘍マーカー
WO2019064073A1 (en) USE OF CA125 FOR PREDICTING ANTI-MESOTHELIC TREATMENT OF MESOTHELIOMES
WO2009150513A2 (en) Protein

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20181129

Address after: new jersey

Applicant after: Eisai Corp.

Address before: American Pennsylvania

Applicant before: Morphotek Inc.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180123